Solid Tumor, Adult
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
32 companies ranked by most advanced pipeline stage
+2 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 40 trials with date data
Clinical Trials (40)
Total enrollment: 2,747 patients across 40 trials
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Study of DF1001 in Patients with Advanced Solid Tumors
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
Study of ASTX029 in Subjects With Advanced Solid Tumors
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
A Study of HMPL-453 in Patients With Advanced Solid Malignancies
A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
First In Human Study of CX-2051 in Advanced Solid Tumors
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
A Study of DCR-STAT3 in Adults With Solid Tumors
Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
First in Human, Dose Escalation, Dose Expansion Study of AUR105
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Systematic Evaluation of Human Explant Model Systems Engineering